Drugs / GSK2202083A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01171989 | Aug → Dec 2010 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01090453 | May 2010 → Oct 2011 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, meningococcal infection +2 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00970307 | Aug 2009 → Jan 2010 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00871741 | Apr → Jun 2009 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, meningococcal infection +2 | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2202083A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00871741 ↗ |
| Modality | Vaccine | “GSK2202083A vaccine” NCT00871741 ↗ |
| Route | Intramuscular | “Intramuscular, three doses” NCT00871741 ↗ |